Vigil Neuroscience (NASDAQ:VIGL – Free Report) had its price target cut by Guggenheim from $17.00 to $16.00 in a research report released on Wednesday, Benzinga reports. They currently have a buy rating on the stock.
Several other brokerages have also issued reports on VIGL. Wedbush reaffirmed an outperform rating and issued a $23.00 target price on shares of Vigil Neuroscience in a research note on Thursday, July 11th. HC Wainwright reaffirmed a buy rating and set a $17.00 target price on shares of Vigil Neuroscience in a report on Wednesday. Finally, JMP Securities reissued a market outperform rating and issued a $23.00 price target on shares of Vigil Neuroscience in a research note on Thursday, April 18th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Vigil Neuroscience currently has an average rating of Moderate Buy and a consensus target price of $16.60.
View Our Latest Report on Vigil Neuroscience
Vigil Neuroscience Stock Performance
Vigil Neuroscience (NASDAQ:VIGL – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.02. On average, analysts predict that Vigil Neuroscience will post -2.1 earnings per share for the current year.
Hedge Funds Weigh In On Vigil Neuroscience
Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Vigil Neuroscience by 11.9% in the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after acquiring an additional 95,276 shares in the last quarter. Ensign Peak Advisors Inc raised its holdings in Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after purchasing an additional 166,442 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after purchasing an additional 11,536 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vigil Neuroscience during the 2nd quarter valued at about $87,000. Finally, Strs Ohio purchased a new position in shares of Vigil Neuroscience during the fourth quarter valued at about $27,000. 83.64% of the stock is owned by hedge funds and other institutional investors.
About Vigil Neuroscience
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Featured Stories
- Five stocks we like better than Vigil Neuroscience
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What Are Trending Stocks? Trending Stocks Explained
- MarketBeat Week in Review – 8/12 – 8/16
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.